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Advances  in  the  optimization  of  in  vitro-transcribed 
mRNA are bringing mRNA-mediated therapy closer to 
reality. In cultured cells, we recently achieved high lev-
els of translation with high-performance liquid chroma-
tography  (HPLC)-purified,  in  vitro-transcribed  mRNAs 
containing  the  modified  nucleoside  pseudouridine. 
Importantly,  pseudouridine  rendered  the  mRNA  non-
immunogenic. Here, using erythropoietin (EPO)-encod-
ing mRNA complexed with TransIT-mRNA, we evaluated 
this new generation of mRNA in vivo. A single injection 
of  100 ng  (0.005 mg/kg)  mRNA  elevated  serum  EPO 
levels in mice significantly by 6 hours and levels were 
maintained for 4 days. In comparison, mRNA containing 
uridine produced 10–100-fold lower levels of EPO lasting 
only 1 day. EPO translated from pseudouridine-mRNA 
was functional and caused a significant increase of both 
reticulocyte counts and hematocrits. As little as 10 ng 
mRNA doubled reticulocyte numbers. Weekly injection 
of 100 ng of EPO mRNA was sufficient to increase the 
hematocrit  from  43  to  57%,  which  was  maintained 
with continued treatment. Even when a large amount 
of pseudouridine-mRNA was injected, no inflammatory 
cytokines were detectable in plasma. Using macaques, 
we could also detect significantly-increased serum EPO 
levels following intraperitoneal injection of rhesus EPO 
mRNA.  These  results  demonstrate  that  HPLC-purified, 
pseudouridine-containing mRNAs encoding therapeutic 
proteins have great potential for clinical applications.
Received 27 October 2011; accepted 11 January 2012; advance online 
publication 14 February 2012. doi:10.1038/mt.2012.7
IntroductIon
Expressing a protein by delivering the encoding mRNA has many 
benefits over methods that use plasmid DNA or viral vectors. 
During mRNA transfection, the coding sequence of the desired 
protein is the only substance delivered to cells, thus avoiding all 
the side effects associated with plasmid backbones, viral genes, 
and viral proteins. Also, the cell-delivered mRNA can be instantly 
translated  even  in  axon  terminals  located  remotely  from  the 
nucleus, because mRNA only requires protein synthesis machin-
ery,  which  is  ubiquitous  throughout  the  cell  cytoplasm.  More 
importantly,  unlike  DNA-  and  viral-based  vectors,  the  mRNA 
does not carry the risk of being incorporated into the genome. 
Considering  these  benefits,  it  is  surprising  that  mRNA-based 
transfection has not become a more common procedure to over-
express therapeutic proteins in vivo.
In 1992, Bloom and colleagues successfully rescued vasopres-
sin-deficient  rats  by  injecting  in  vitro-transcribed  vasopressin 
mRNA into the hypothalamus.1 This represents the first and, until 
2011, the only study where in vitro-transcribed mRNA is used 
for gene replacement in vivo. For many years, immunization with 
mRNA coding for cancer antigens has been the only field of appli-
cation where direct injection of in vitro transcripts was success-
fully used, even reaching clinical trials.2–5 For this application, the 
low levels of translation and the immunogenicity of the mRNA 
were not limiting factors, but those two characteristics greatly 
restricted the exploitation of mRNA for many other in vivo and 
ex vivo applications.
As we and others have shown, in vitro transcribed RNA is 
immunogenic, activating cell surface, endosomal, and cytoplasmic 
RNA sensors, including Toll-like receptor (TLR) 3, TLR7, TLR8,6–8  
retinoic acid-inducible gene I (RIG-I),9 RNA-dependent protein 
kinase (PKR),10,11 and the 2′-5′-oligoadenylate synthetase/RNase 
L axis.12 However, when modified nucleosides, such as pseudouri-
dine, were incorporated into the RNA, it no longer activated TLR7, 
TLR8,8  RIG-I,9  PKR,11,13 a n d  2 ′-5′-oligoadenylate  synthetase.12 
More importantly, pseudouridine-containing mRNA (Ψ-mRNA) 
was not only translatable, but higher amounts of protein were 
produced compared to uridine-containing mRNA (U-mRNA).14 
This was partly due to increased resistance of Ψ-mRNA to RNase 
L-mediated cleavage12 and a lack of PKR activation.11
Recently, Kormann et al. reported a successful in vivo use of 
modified nucleoside-containing mRNAs to express therapeutic 
proteins in mice.15 Incorporation of both 5-methylcytidine and 
2-thiouridine into the mRNAs was critical for this accomplish-
ment, since those reduced, although did not completely elimi-
nate, immune activation. We achieved robust improvement in the 
translational capacity of Ψ-mRNA through high-performance liq-
uid chromatography (HPLC) purification, which also completely 
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eliminated  immunogenicity  when  tested  in  vitro.16  Therefore, 
we  were  interested  in  testing  the  performance  of  these  newly 
perfected  mRNAs  in  vivo.  We  selected  erythropoietin  (EPO)-
encoding mRNAs for our evaluation, since detecting the effect of 
EPO on red blood cell production, by measuring reticulocyte lev-
els and the hematocrit from whole blood, is straightforward and 
well-established.
Using  HPLC-purified  EPO-encoding  Ψ-mRNA  complexed 
with TransIT-mRNA (TransIT), a nonliposomal cationic polymer/
lipid formulation, we demonstrate that injection of submicrogram 
amounts into mice is sufficient to significantly increase the levels 
of reticulocytes and the hematocrit without an induction of cir-
culating proinflammatory cytokines [interferon-α (IFN-α), tumor 
necrosis factor-α (TNF-α), and interleukin-6 (IL-6)]. The presence 
of pseudouridine in the mRNA was critical, since HPLC-purified 
EPO U-mRNA induced IFN-α and had no significant effect on 
erythropoiesis. Extension of these preliminary studies into rhe-
sus macaques similarly demonstrated the ability of systemically 
administered EPO-encoding Ψ-mRNA complexed with TransIT 
to produce significant amounts of circulating EPO without induc-
ing proinflammatory cytokines. These results demonstrate that 
HPLC-purified,  pseudouridine-containing  mRNAs  encoding 
therapeutic proteins have great potential for clinical applications.
results
To identify the optimal murine EPO mRNA for use in vivo, we 
generated sets of mRNAs and tested their translational capacity 
in human dendritic cells (DCs). DCs efficiently translate exoge-
nously delivered mRNA and express all known RNA sensors, such 
as TLR3, TLR7, TLR8, RIG-I, MDA-5, and PKR.17 All the features 
that are known to improve translation were incorporated into 
the transcripts. The mRNAs were HPLC purified and contained 
the 5′-UTR derived from the tobacco etch virus 5′ leader RNA, 
3′-UTR of Xenopus β-globin mRNA, an enzymatically-generated 
cap1 structure, and a plasmid-encoded 51 nt-long poly(A) tail, 
which was extended to ~200 nt-long using poly(A) polymerase. 
Either pseudouridine or uridine was incorporated into the syn-
thesized mRNAs. Codon optimization was used to increase trans-
lation  further.  The  codon-optimized  EPO  mRNAs  contained 
hybrids of AU- and GC-rich codons that have been reported to 
increase translation of human EPO mRNA.18 Indeed, the high-
est level of translation and a complete lack of proinflammatory 
cytokine secretion were achieved from pseudouridine-containing 
mRNA that was codon-optimized (Figure 1 and data not shown); 
therefore, we used this mRNA for subsequent in vivo analysis. 
For simplicity, we labeled this RNA as EPO Ψ-mRNA and the 
corresponding  control  mRNA  that  contained  uridine  as  EPO 
U-mRNA.
To determine if EPO mRNA administered in vivo can elevate 
blood EPO levels, adult mice were intraperitoneally (i.p.) injected 
with  EPO  mRNA  (0.1 µg)  complexed  with  TransIT.  A  sharp 
increase in serum EPO levels were measured, reaching a maxi-
mum at 6 hours postinjection (Figure 2a). Remarkably, EPO levels 
remained elevated up to 4 days after EPO Ψ-mRNA administra-
tion, while EPO U-mRNA resulted in much lower EPO levels that 
returned to pre-injection baseline levels by day 2. The injection of 
3-µg recombinant murine EPO could not be detected beyond 6 
hours postinjection, suggesting a rapid half-life, in agreement with 
studies that found a half-life for exogenously delivered EPO in 
mice of about 2 hours.19 Therefore, the high EPO levels we detected 
up to 4 days following a single injection are best explained by sus-
tained translation of EPO Ψ-mRNA. When tenfold more (1.0 µg) 
EPO Ψ-mRNA complexed with TransIT was injected, a propor-
tional tenfold higher EPO level was detected in the blood (data 
not shown). To determine if the injected EPO mRNA produces 
functional EPO protein, we counted reticulocytes in the treated 
animals. Reticulocytes are circulating immature red blood cells 
and their blood level is proportional to the rate of new red blood 
cell  formation.  In  a  dose  escalation  experiment,  we  gave  EPO 
Ψ-mRNA (0.001–10 µg) complexed with TransIT to groups of mice 
and monitored blood reticulocyte levels. Significant increases in 
the levels of reticulocytes were measured as early as day 3 postin-
jection, reached a maximum at day 5, remained elevated at day 
7, and declined to baseline (~5%) by day 10 (Figure 2b). Using 
human EPO protein, which is functional in mice, as a comparison, 
the reticulocyte level returned to baseline by day 7 (Figure 2b). 
There  was  a  dose-dependent  relationship  between  the  amount 
of Ψ-mRNA injected, up to 1 µg, and the increase in circulating 
reticulocytes. It is remarkable that 0.001 µg EPO Ψ-mRNA was as 
potent as 1 µg of EPO U-mRNA in increasing reticulocyte counts 
(Figure 2b). It is worth mentioning that both subcutaneously and 
intramuscularly injected EPO Ψ-mRNA also raised reticulocyte 
counts significantly (data not shown), although not as potently as 
the i.p.-delivered mRNA. We found no elevation of reticulocyte 
counts at any time point when luciferase-encoding Ψ-mRNA com-
plexed with TransIT was injected (Figure 2b), demonstrating that 
the effects were not due to Ψ-mRNA injection but to functional 
EPO translation from the exogenous EPO Ψ-mRNA (Figure 2b).
Since ~1 µg EPO Ψ-mRNA produced a maximal effect, elevat-
ing the reticulocyte counts from a pre-injection level of 5% to 20% 
5 days after injection, we used 1 µg mRNA to determine the physi-
ological impact of EPO Ψ-mRNA on the hematocrit. As shown in 
Figure 2c, i.p. injection of TransIT-complexed EPO Ψ-mRNA led to 
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Figure 1  codon-optimized, pseudouridine-containing murine eryth-
ropoietin (ePo) mrnA yields the highest level of translation. Human 
dendritic  cells  (DCs)  were  treated  with  TransIT-complexed  in  vitro-
transcribed mRNA (0.1 µg/well) with the wild-type or codon-optimized 
sequence of murine EPO containing uridine (U-mRNA) or pseudouridine 
(Ψ-mRNA). The levels of EPO in the supernatants were measured by 
enzyme-linked immunosorbent assay (ELISA) 24 hours later. Error bars 
are standard errors of the mean (SEM). The data shown is one of three 
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a significant increase in the hematocrit as early as 3 days after injec-
tion and reached maximum at day 6. The hematocrit was still sig-
nificantly elevated 2 weeks after injection. Injection of 1 µg of EPO 
U-mRNA or luc Ψ-mRNA did not result in a significant elevation 
of the hematocrit at any time point (Figure 2c), thus demonstrat-
ing pseudouridine incorporation is critical for efficient translation. 
We also found that an elevated hematocrit could be maintained 
with  weekly  injections  of  0.1 µg  EPO  Ψ-mRNA  complexed  to 
TransIT. The preinjection hematocrit was raised, from 43.2 ± 1.5% 
up to 57.7 ± 1.1%, and maintained during the 5-week course of 
treatment (Figure 2d). Certain formulations of EPO protein given 
to humans20,21 and EPO gene therapy given to macaques22,23 have 
resulted in serious autoimmune reactions directed at EPO. Serum 
from mice that received 5 weekly injections of TransIT-complexed 
EPO Ψ-mRNA were analyzed for the presence of antibodies that 
bound  to  murine  EPO  protein  in  a  sandwich  enzyme-linked 
immunosorbent assay (ELISA) and none were detected. The assay 
could detect as little as 0.1 ng/ml of anti-EPO antibody in plasma.
We  recently  demonstrated  that  mRNA  complexed  with 
TransIT  does  not  induce  IFN-α  secretion  from  transfected 
human DCs, as long as the RNA contains pseudouridine and 
is  purified  by  HPLC.16  It  was  therefore  important  for  us  to 
determine whether or not EPO Ψ-mRNA remains nonimmuno-
genic in vivo. We injected mice with TransIT-complexed EPO 
Ψ-mRNA  or  EPO  U-mRNA  (1 µg)  i.p.  and  measured  serum 
IFN-α, TNF-α and IL-6 levels at 6 hours postinjection. While 
the uridine-containing EPO mRNA was highly immunogenic, 
resulting in robust induction of IFN-α measured from plasma, 
IFN-α was not induced in mice injected with EPO Ψ-mRNA 
(Figure 2e). The levels of TNF-α and IL-6 in the plasma of EPO 
Ψ-mRNA and EPO U-mRNA injected mice were at background 
levels (data not shown).
In a pilot study, we delivered a single injection of TransIT-
complexed rhesus EPO-encoding Ψ-mRNA (rhEPO Ψ-mRNA) to 
macaques and measured circulating EPO levels. The i.p. injected 
rhEPO Ψ-mRNA elevated the levels of plasma EPO with kinetics 
similar to those observed in mice (Figure 3). No increase in the 
levels of serum type I IFNs, TNF-α, and IL-6 were detected after 
any dose of rhEPO Ψ-mRNA measured at 6–48 hours postinjec-
tion (data not shown).
dIscussIon
Our study demonstrates the feasibility of using in vitro transcribed 
mRNA to express therapeutic proteins in vivo. As a model system, 
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Adult mice were injected intraperitoneally (i.p.) with TransIT-complexed mRNA (0.1 µg) coding for murine EPO containing pseudouridine (EPO 
Ψ-mRNA) or containing uridine (EPO U-mRNA) or coding for firefly luciferase and containing pseudouridine (luc Ψ-mRNA) or with 3 µg of recombi-
nant murine EPO (rmEPO) protein. Serum EPO levels were measured by enzyme-linked immunosorbent assay (ELISA) at the indicated time points. Five 
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we used EPO-mediated induction of erythropoiesis to show the 
efficacy of mRNA-based therapy. We demonstrate in mice that 
a  single  dose  of  0.1 µg  EPO-encoding  mRNA  complexed  with 
TransIT is sufficient to increase blood EPO levels as early as 6 
hours postinjection and high levels are maintained for 4 days. As 
little as 0.01 µg EPO mRNA doubled the circulating reticulocyte 
count. We also demonstrate that the injected TransIT-complexed 
mRNA does not induce adverse side-effects or detectable increases 
in circulating proinflammatory cytokines. These remarkable fea-
tures were achieved by a combination of incorporating pseudou-
ridine into the mRNA and purifying by HPLC.
In our previous studies, we demonstrated that Ψ-mRNA pos-
sesses superior translational properties.14 The mechanisms under-
lying  its  enhanced  translational  quality  include:  (i)  diminished 
PKR  activation,  thereby  reducing  translational  inhibition,11  (ii) 
a stabilizing effect on the RNA by increasing resistance to RNase 
L-mediated  cleavage,12  and  (iii)  a  lack  of  2′-5′-oligoadenylate 
synthetase activation and ribosomal RNA cleavage, thus avoid-
ing a global reduction in translation.12 We also demonstrated that 
pseudouridine,  similar  to  other  modified  nucleosides,  reduced 
RNA-elicited  innate  immune  responses.8  Recently,  we  further 
improved  the  quality  of  pseudouridine-containing  RNA  with 
HPLC  purification.16  We  found  that  HPLC  removed  double-
stranded  RNA  and  other  contaminants  from  the  in  vitro-tran-
scribed RNA, thereby maximizing its translational efficiency, as 
well as eliminating any residual immunogenicity. In this report, we 
demonstrate that HPLC-purified, pseudouridine-containing RNA 
complexed with TransIT, possessing very high translational capac-
ity with no detectable immunogenicity, is not only effective in vivo 
but requires doses that will allow pharmacological development.
Despite much progress in the field, the immune activation 
caused  by  viral  and  plasmid  vectors  remains  one  of  the  pri-
mary reasons for failure in human gene therapy trials.24 Adverse 
immune reactions also emerge when administering therapeutic 
proteins.25 Examples of both include, respectively; induction of 
anti-EPO antibodies and severe autoimmune anemia when EPO-
expressing viral vectors were used in monkeys,22,23 and patients 
treated with an altered formulation of recombinant EPO protein 
developed  anti-EPO  neutralizing  antibodies  and  transfusion-
dependent  anemia.20,26  Thus,  avoiding  an  immune  reaction  is 
essential for effective protein replacement, regardless if it is per-
formed by directly supplying the protein or via an encoding vec-
tor. Using nucleoside-modified mRNA coding for the therapeutic 
protein seems the optimal choice. Kormann et al. recently used 
nucleoside-modified mRNA in vivo, and the innate immune reac-
tion to the injected mRNA was limited but not completely abol-
ished.15 Their mRNA construct still induced cytokine production, 
although at a lower level than unmodified mRNA. The residual 
immune  activation  was  likely  caused  by  transcription-related 
aberrant RNA contaminants; however, those contaminants, as we 
have found, are removable by HPLC-purification,16 thus making 
the nucleoside-modified mRNA nonimmunogenic (Figure 2e).
Generating  constructs  with  codon-optimized  sequences  is 
another  method  to  maximize  protein  expression.27  Mammalian 
codons usually have G or C in their third degenerative position, and 
such sequences are expressed more efficiently than those in which 
the codons end with A or T.28 High expression levels of human EPO 
were reported using a chimeric construct in which the N-terminal 
part of EPO was coded by sequences enriched in AT-ending codons, 
whereas  the  remaining  part  of  EPO  was  coded  by  GC-ending 
codons.18 In the present study, we adopted this codon-optimization 
strategy for our murine EPO. Typically, codon optimizations are 
performed by comparing protein production from DNA plasmids 
carrying the wild-type sequence to the optimized sequence.28 In 
this setting, it is difficult to sort out if the increased protein expres-
sion from the codon-optimized construct is caused by enhanced 
transcription, increased RNA stability, or augmented translation. 
However, one study compared translation of cell-delivered wild-
type and codon-optimized RNAs directly and, similar to our results 
with the Ψ-mRNAs (Figure 1), found an increase in protein pro-
duction from the codon-optimized mRNA.29
As an extension to our analysis in mice, we were able to perform 
a short pilot study in rhesus macaques. HPLC-purified TransIT-
complexed Ψ-mRNA encoding rhesus EPO was delivered i.p. at 
doses similar to those we used in mice, and we observed a sub-
stantial increase in circulating EPO. Due to limitations, including 
cost, time constraints, and the small cohort of macaques, we were 
unable to perform experiments where the hematological responses 
to EPO induction could have been measured. Regardless, and more 
importantly, no adverse effects were observed and no increase in 
levels of IFN-α, TNF-α, and IL-6 were found. Future studies are 
needed to optimize both the route of delivery and the formula-
tion of complexing agent for primate studies. An initial evalua-
tion in the macaques using subcutaneous injection, which is the 
preferred therapeutic route, found levels of circulating EPO at 48 
hours that were similar to those measured at 24 hours, suggesting 
prolonged production and release.
mRNA therapy could be a promising approach for express-
ing proteins and the treatment of inherited genetic disorders. At 
present, extracellular proteins that are administered to patients, 
including  type  I  IFNs,  monoclonal  antibodies,  and  adenosine 
deaminase,  can  successfully  treat  their  conditions.  However, 
delivering or replacing an intracellular protein requires alterna-
tive approaches, such as gene therapy. HPLC-purified, pseudou-
ridine-modified mRNA offers a new approach to the therapeutic 
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expression of both extra- and intracellular proteins. It avoids the 
two major adverse events found clinically with other gene therapy 
approaches, vector immunogenicity,30,31 and chromosomal inte-
gration.32 A limitation of mRNA delivery compared with integra-
tive gene transfer is the transient duration of protein expression. 
However,  there  are  many  pathological  disorders  that  can  be 
treated with transient expression of therapeutic proteins. In addi-
tion, unless an integrative gene therapy approach targets the stem 
cells of interest, it will need to be repeated at a duration associated 
with the half-life of the cells being targeted. mRNA therapy has 
the added benefits that the dosing is scalable and the treatment 
stops when the RNA and the encoded protein degrade. Adapting 
mRNA delivery to therapeutics will require continued improve-
ment in mRNA translational capacity, safe and efficient techniques 
to deliver mRNA to specific cells or tissues, a better understanding 
of the molecular mechanisms mediating mRNA uptake, and opti-
mization of the large-scale production of mRNA for clinical use.
MAterIAls And Methods
Cells.  Human  monocyte-derived  DCs  were  produced  as  described 
previously.33
Animal experiments. All experiments were carried out with the approval 
of the Institutional Animal Care and Use Committee (IACUC) of the 
University of Pennsylvania. BALB/c female mice from Jackson Laboratory 
(Bar Harbor, ME), aged 6–12 weeks, were used. Macaques were housed and 
experiments were performed at Bioqual (Rockville, MD). They are accred-
ited by the Association for Assessment and Accreditation of Laboratory 
Animal  Care  International  (AAALAC)  and  meet  National  Institutes 
of Health standards as described in the Guide for the Care and Use of 
Laboratory Animals. The University of Pennsylvania IACUC approved all 
experiments carried out by Bioqual.
mRNA synthesis. mRNAs were transcribed as previously described,14 using 
linearized plasmids encoding wild-type and codon-optimized murine EPO 
(pTEVwtEPO and pTEVoptEPO), firefly luciferase (pTEVLuc), and rhe-
sus macaque EPO (pTEVrhEPO). The rhesus EPO and codon-  optimized 
mouse EPO genes were synthesized by Entelechon (Bad Abbach, Germany). 
Codons for the mouse EPO gene were selected based on Entelechon’s pro-
prietary algorithm and codon-optimized human EPO.18 The Megascript 
T7 RNA polymerase kit (Ambion, Austin, TX) was used for transcription, 
and UTP was replaced with pseudouridine triphosphate (TriLink, San 
Diego,  CA)  to  generate  pseudouridine-containing  mRNA.  All  mRNAs 
were transcribed to contain 51-nt long poly(A) tails. Additional poly(A) 
tail  was  added  in  a  3-hour  incubation  with  yeast  poly(A)  polymerase 
(USB, Cleveland OH). To obtain cap1, RNA was processed using the m7G 
capping and 2′-O-methyltransferase kits (CellScript, Madison, WI). All 
mRNAs were HPLC-purified as described.16
Complexing of RNA. RNA was complexed to TransIT-mRNA (Mirus Bio, 
Madison, WI) according to the manufacturer. A ratio of mRNA (0.1 µg), 
TransIT-mRNA reagent (0.11 µl), and Boost reagent (0.07 µl) in a final vol-
ume of 10 µl Dulbecco’s modified Eagle’s medium was used. For complex-
ing different amounts of mRNA the volumes of the reagents and the final 
volume were scaled proportionally.
i.p. injection of TransIT-complexed mRNA into mice. Blood, <25 μl, was 
drawn from the tail vein before treatments to establish baseline param-
eters. The mRNA and EPO proteins were injected into the peritoneal cavity 
with a 27-gauge needle using standard technique.
Measuring EPO levels and determining hematocrit. Translational levels 
of wild-type and codon-optimized EPO mRNAs were measured in human 
DCs. Cells were seeded into 96-well plates (1.5 × 105 cells/well) in 190 µl 
of complete medium and transfected by adding 0.1 µg mRNA complexed 
with TransIT in a 10-µl final volume. Mouse EPO levels were measured 
in the culture medium 24 hours post-transfection using a mouse EPO 
ELISA kit (R&D Systems, Minneapolis, MN). The same kit was used to 
measure EPO levels in the plasma of animals (5 mice/group) that were 
injected with either RNA complexed with TransIT or with 3 µg of recom-
binant mouse EPO protein (Sigma-Aldrich, St Louis, MO). Since blood 
was being drawn repeatedly, it was essential to minimize the volume so 
the sampling would not affect the hematological parameters of the ani-
mals. Eighteen microliter of blood was mixed with 2 µl EDTA (0.2 mol/l) 
and  placed  into  a  20 µl  Drummond  microcaps  glass  microcapillary 
tube (Sigma-Aldrich). After sealing one end of the tubes with Cha-seal 
(Chase Scientific Glass, Rockwood, TN), the capillary tubes were centri-
fuged in IEC MB Microhematocrit Centrifuge (DAMON/IEC Division, 
Needham, MA) for 3 minutes at 14,000 rpm. Capillary tubes were scanned 
(ScanMaker; Microtek, Santa Fe, CA) and digital images of the tubes were 
imported into Canvas X (ADB System, Seattle, WA) and the packed cell 
volume ratio was determined. After determining the hematocrit, capillary 
tubes were snapped and the plasma was collected for the measurement of 
plasma EPO levels.
Reticulocyte counts. Five microliter of blood drawn from the tail vein of 
BALB/C  mice  (3–11  animals/group)  injected  with  TransIT-complexed 
mRNA (0.001–10 µg) or with 100 U of recombinant human EPO (Epogen; 
Amgen, Thousands Oaks, CA) was mixed with 0.5 µl EDTA (0.2 mol/l) and 
analyzed using Retic-COUNT, a thiazole orange reagent (BD Biosciences, 
San Jose, CA), as recommended by the manufacturer. Stained cells were 
analyzed on a FACScalibur flow cytometer using CellQuest software (BD 
Biosciences). Values are expressed as the percentage of reticulocytes rela-
tive to total erythrocytes.
Measuring IFN-α, TNF-α, and IL-6. BALB/c mice injected with TransIT-
complexed mRNA (1 µg) were processed 6 hours later by injecting 100 µl 
of heparin (Abraxis, Schaumburg, IL) i.p. and sacrificed. ELISA was used 
to measure the levels of IFN-α (R&D Systems), TNF-α and IL-6 (Cell 
Sciences, Sharon, MA) in undiluted plasma.
Analysis of EPO-specific antibody responses. A sandwich ELISA was used 
to measure the development of murine antibody responses to EPO pro-
tein. Plasma from mice injected weekly for 5 weeks with 0.1 µg of EPO 
or luc Ψ-mRNA was diluted 1:10 in phosphate-buffered saline and added 
to murine EPO protein coated plates. A positive control containing a rat 
anti-murine EPO mAb (R&D Systems) spiked into normal mouse plasma 
was used. Bound antibodies were detected with goat anti-mouse and rat Ig 
antisera labeled with peroxidase. A concentration of 0.1 ng/ml of anti-EPO 
antibody spiked into plasma-phosphate-buffered saline could be detected.
Macaque experiments. Two- to three-year-old Rhesus macaques (n = 4) 
were bled and injected with TransIT-complexed mRNA i.p. using standard 
procedures. Plasma for rhesus EPO was analyzed undiluted in a human 
EPO-specific ELISA kit that crossreacts with rhesus EPO (R&D Systems). 
The ELISA underestimates rhesus EPO by approximately fourfold.34 The 
uncorrected ELISA readings are given. Rhesus-specific ELISAs were used 
to measure the levels of IFN-α (PBL Interferon Source, Piscataway, NJ), 
TNF-α, and IL-6 (Cell Sciences) in undiluted plasma.
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